433 studies found for:    PAH
Show Display Options
Rank Status Study
21 Recruiting National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention:
22 Recruiting Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension
Conditions: Muscle Weakness;   Pulmonary Arterial Hypertension
Intervention:
23 Unknown  Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
Conditions: Pulmonary Arterial Hypertension;   Idiopathic Pulmonary Fibrosis
Interventions: Drug: bosentan;   Other: No specific intervention
24 Unknown  Pharmacogenomics in Pulmonary Arterial Hypertension
Conditions: Pulmonary Arterial Hypertension;   Pulmonary Hypertension;   PAH WHO Group I
Interventions: Drug: Sitaxsentan;   Drug: Bosentan, Ambrisentan
25 Recruiting The Expression and Significance of MiRNA
Condition: Pulmonary Arterial Hypertension
Intervention:
26 Recruiting SYMPHONY: A Study of Macitentan in Pulmonary Arterial Hypertension to Validate the PAH-SYMPACT
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Macitentan
27 Completed Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Imatinib
28 Active, not recruiting Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Selexipag (ACT-293987);   Drug: Placebo
29 Completed Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Beraprost Sodium Modified Release
30 Completed
Has Results
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Ambrisentan;   Drug: Placebo;   Drug: Sildenafil;   Drug: Tadalafil
31 Completed
Has Results
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: macitentan (ACT-064992);   Drug: placebo
32 Active, not recruiting DelIVery for Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Device: The Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System to deliver Remodulin Injection
33 Withdrawn Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Iloprost Inhalation Solution (Ventavis)
34 Recruiting A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain
Condition: Pulmonary Arterial Hypertension (PAH)
Intervention: Drug: Macitentan
35 Active, not recruiting Long-term Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: ACT-064992
36 Completed A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Beraprost sodium modified release
37 Completed Smoking: a Risk Factor for Pulmonary Arterial Hypertension?
Condition: Pulmonary Hypertension
Intervention:
38 Completed 6R-BH4 Pulmonary Arterial Hypertension Study
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: sapropterin dihydrochloride (6R-BH4)
39 Recruiting Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Conditions: Pulmonary Arterial Hypertension;   Hypertension, Pulmonary
Intervention: Drug: Sildenafil
40 Completed Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Sorafenib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years